Guideline-Based Chinese Herbal Medicine Treatment Plus Standard Care for Severe Coronavirus Disease 2019 (G-CHAMPS): Evidence From China

  1. Yong-an Ye
  2. The G-CHAMPS Collaborative Group

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. ScreenIT

    SciScore for 10.1101/2020.03.27.20044974: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: The trial was approved by the ethics committee at Dongzhimen Hospital (No. DZMEC-KY-2020-09).
    Consent: Inclusion criteria comprised of: adult patients (≥ 18 years), positive test results for SARS-CoV-2 on a polymerase-chain-reaction (PCR) assay, respiratory rate (RR) ≥ 30/min or SaO2≤93% or a PaO2/FiO2 ratio ≤300mmHg(4), and able to provide informed consent.
    RandomizationStudy design: This was an open-label, pilot, randomized trial for severe COVID-19.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc) with a 2-sided p value of less than .
    SAS Institute
    suggested: (Statistical Analysis System, RRID:SCR_008567)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Our study has several limitations, including an open-label design, a small sample size. Additionally, this study lacks long term outcomes and the COVID-19 disease severity scale deserves further investigation. Despite these substantial limitations, the G-CHAMPS trial provided an important opportunity to better understand CHM for severe COVID-19. For the first time, the G-CHAMPS trial provided valuable information for the national guideline-based CHM treatment for hospitalized patients with severe COVID-19. As effective antiviral treatment is still lacking for COVID-19 and SARS-CoV-2 continues to spread outside of China(9), all potentially effective treatments including CHM worth vigorous further investigation.

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    NCT04257656TerminatedA Trial of Remdesivir in Adults With Severe COVID-19

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  2. Version published to 10.3389/fmed.2020.00256
  3. Version published to 10.1101/2020.03.27.20044974v1 on medRxiv